23 February 2023 
EMA/CHMP/64403/2023 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Esbriet 
pirfenidone 
On 23 February 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Esbriet. The marketing authorisation holder for this medicinal product is Roche Registration GmbH. 
The CHMP adopted a change to the existing indication to include treatment of ‘advanced’ idiopathic 
pulmonary fibrosis (IPF). For information, the full indication for Esbriet will be as follows:2  
  Esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 Removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
